RCT
Open-label
randomly assigned
Answers are grounded in this paper and cite their sources.
Summary. Patients with coronary heart disease (CHD) or coronary risk equivalent receiving statin therapy and with low low-density lipoprotein (LDL) cholesterol levels and low high-density lipoprotein (HDL) cholesterol levels were randomized to received extended-release niacin or ezetimibe. The combination of a statin with niacin was more efficacious than a statin/ezetimibe in reducing mean and maximum carotid intima-media thickness (CIMT) over 14 months. Background. The study was aimed at determining whether greater reduction in LDL cholesterol levels or effects on other lipid values could further modify the relative risk for cardiovascular (CV) events, in this case using CIMT as a surrogate. Study Design. Men and women aged ≥30 years with atherosclerotic coronary or vascular disease or CHD risk equivalent by Framingham risk score or a high coronary calcium score were randomized. All participants were to be on a stable dose of a statin and have a baseline LDL cholesterol level <100 mg/dL and HDL cholesterol level <50 mg/dL for men and <55 mg/dL for women. Participants were randomly assigned to open-label extended-release niacin up to 2000 mg/d or ezetimibe 10 mg/d. The primary end point was between-group difference in the change in baseline mean CIMT after 14 months. Results. In terms of the baseline data, the mean LDL cholesterol levels ranged between 81 and 84 mg/dL in the 2 groups (not significant) and the mean HDL cholesterol level was 43 mg/dL. Triglyceride values averaged 124 mg/dL. Changes in lipid levels are shown in Figure 1. In the statin/niacin group, HDL cholesterol levels increased up to 20% from baseline at 8 months and 18% of baseline at 14 months. A decrease of 5% from baseline was found in the statin/ezetimibe group after 14 months. LDL cholesterol decreased in both groups, most of the decrease occurring at 2 months: −16% in the niacin group and −17% in the ezetimibe group. Triglycerides decreased slightly; levels returned to baseline at 14 months in the ezetimibe group but were significantly decreased (−16%) in the niacin group. For primary outcome, the niacin group showed a significant reduction in mean CIMT after 14 months, while there was no evident change in the ezetimibe group (P=.003 for differences between groups, P=.001 for decrease from baseline in the niacin group, Figure 2). Similar results were evident for maximal CIMT thickness. Major adverse CV events occurred in more patients in the ezetimibe group than in the niacin group (5% vs 1%, P=.04). No differences were found in quality of life, but adherence to study medication was slightly lower in the niacin group (88% vs 95% for ezetimibe). However, 75% of participants in the niacin group received the maximum dose of 2000 mg/d. On the basis of the primary findings, the trial was terminated early. However, because of premature termination of the trial, 40% of patients did not undergo the carotid end point determination at 14 months. Mean percentage changes in cholesterol and triglyceride levels over the 14-month study period among 208 patients who completed the study, by treatment group. From reference 1 with permission from the Massachusetts Medical Society © 2009. Changes in mean carotid intima-media thickness over the 14-month study period by treatment group. From reference 1 with permission from the Massachusetts Medical Society © 2009. Comment. What intervention is necessary in a patient at high risk for coronary events with an acceptable LDL cholesterol level (<100 mg/dL) but with a relatively low HDL cholesterol level? There has previously been no extensive evaluation of the efficacy of interventions in this situation. The present study demonstrated the efficacy of a combination of a statin with niacin over a statin with ezetimibe based on the primary end point of reduction in CIMT, a surrogate marker, but was suggestive of benefit in mitigating the advance of atherosclerosis. The benefit of the addition of niacin to a statin could be attributed either to the increase in HDL cholesterol levels (compared with the statin/ezetimibe combination) or to pleiotropic effects.2 There is a paucity of evidence that elevation of HDL cholesterol itself by pharmacologic means is beneficial, and in the case of torcetrapib it has been shown to be harmful.3 Whether the effect of CIMT can be extrapolated to decreased coronary events is indeed speculative, and as pointed out in an accompanying editorial,2 measures of carotid plaque volume are more closely correlated with changes in atherosclerosis volume than thickness.4 It is intriguing that the study results demonstrated the benefit of niacin despite the lower LDL cholesterol level reached with the statin/ezetimibe combination. Does this mean that once the LDL cholesterol level reaches a certain low point, further reduction is not of benefit? Certainly not from the results of the Pravastatin or Atorvastatin Evaluation and Infection Therapy - Thrombolysis in Myocardial Infarction 22 (PROVE IT - TIMI 22) analysis.5 Finally, how do we explain the difference in major CV events that developed between groups in 14 months? Certainly a 1% rate in the niacin group is relatively low, but a 5% rate in the ezetimibe group extrapolated to 10 years would suggest at least a 30% to 40% rate, well above the “high risk” standard. It is possible that the effects of ezetimibe may have some adverse actions on HDL cholesterol–mediated reverse transport of cholesterol by inhibition of a scavenger receptor participating in HDL cholesterol binding.6 Several large clinical trials of combinations with a statin and niacin or ezetimibe are under way that would further evaluate this issue. These include the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT), Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE), and Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health (AIM-HIGH). Summary. In 6860 Framingham Heart Study participants free of coronary heart disease at baseline, HDL cholesterol and non-HDL cholesterol levels were evaluated for dyslipidemia-specific population burden for heart failure (HF) over a mean of 26 years. Participants with high baseline non-HDL cholesterol and low HDL cholesterol experienced a 29% to 40% increased risk of HF compared with those with desirable lipid values at baseline. Background. There is evidence from epidemiologic studies for an association of lipid levels with HF.8 There is a paucity of evidence, however, for a systematic community-based risk assessment for HF in persons without preexisting CHD. By adjustment for clinical factors including interim myocardial infarction (MI), the independent effects of lipid levels on HF development could be evaluated. Study Design. Attendees at periodic examinations in Framingham of the original and offspring cohort examined in periods between 1968 and 1974 were evaluated who did not have baseline HF, MI, angina pectoris, valvular disease, or use of lipid therapy at baseline. Documentation of HF by ongoing review of clinic charts, hospitalization and physician records, and mailed health history updates were used for evaluation of outcome. Covariates evaluated included body mass index, current smoking, diabetes mellitus, interim MI (before development of HF), and hypertension. Results. Over a mean follow-up of 26 years, a first HF event developed in 680. Of these, 41% during the prospective evaluation period had a preceding MI before HF developed. For primary outcome evaluation, population attributable risk for high non-HDL cholesterol was 7.5% and for low HDL cholesterol, 15%. Of those with HF, the percentage with interim MI increased with increasing categories of non-HDL cholesterol (from 33% to 48%) and with decreasing categories of HDL cholesterol (from 28% to 48%). Unadjusted HF rates in the low (<160 mg/dL) vs high (≥190 mg/dL) non-HDL cholesterol levels increased from 7.9% to 13.8%. For HDL cholesterol levels, HF rates increased from 6.1% to 12.8% as HDL cholesterol levels decreased from ≥55 mg/dL to <40 mg/dL for men and from ≥65 mg/dL to <50 mg/dL for women. In terms of percentage increase in risk, high non-HDL cholesterol levels increased HF risk by 29% compared with low levels, and low HDL cholesterol levels increased risk by 40% compared with high levels. Complex analysis of covariates yielded the following results. Using baseline lipid values adjusted for covariates, not including interim MI, increased HDL cholesterol demonstrated lower risk for developed HF (hazard ratio [HR], 0.82; 95% confidence interval [CI], 0.75–0.90), and non-HDL cholesterol demonstrated higher risk (HR, 1.19; 95% CI, 1.11–1.27). These risk results, although attenuated, remained significant when adjusted for interim MI (HDL cholesterol, 0.89; non-HDL cholesterol, 1.10). If evaluated by lipid levels updated every 8 years, these results also obtained with HRs slightly lower for increased HDL cholesterol and higher for increased non-HDL cholesterol. Comment. There is little information about the role of dyslipidemia in HF risk, especially in those without previous CHD. The best way to evaluate the potential risk is to follow persons without CHD and HF to determine the independent risk of lipid levels. This was accomplished over a long term of 26 years in the Framingham cohorts. After adjustment for the incidence of MI and other variables, elevated non-HDL cholesterol (≥190 mg/dL) and low HDL cholesterol (<40 mg/dL in men and <50 mg/dL in women) explained 22.5% of the occurrence of HF. Several previous reports from Framingham8,9 demonstrated an association between dyslipidemia and HF risk, and dietary intakes leading to dyslipidemia or the metabolic syndrome have also been associated with HF.9–12 The presumed protective benefit of high HDL cholesterol, or increased risk of high non-HDL cholesterol, may be partially explained by effects on inflammation.13,14 The investigators did not account for possible effects of ancillary agents such as angiotensin-converting enzyme inhibitors, diuretics, or β-blockers, and triglycerides and LDL cholesterol levels were not assessed but placed under the category of non-HDL cholesterol. The diagnosis of HF was not indicated directly in the manuscript but referred to a classification made in 197115 that did not include later echocardiographic assessment that could have indicated more specific categorization of the type of HF (systolic or diastolic, for example) (see Table). However, the epidemiologic assessment suggests that dyslipidemia effects on inflammation may increase risk of HF, possibly through the associated effects on blood pressure, itself a strong risk factor for HF.
No takes yet. Share an insight, caveat, or question.
Philip R. Liebson (2010) conducted an RCT in Atherosclerotic coronary or vascular disease or CHD risk equivalent. Extended-release niacin vs. Ezetimibe 10 mg/d was evaluated on Between-group difference in the change in baseline mean carotid intima-media thickness (CIMT) after 14 months (p=0.003).
Synapse has enriched 10 related papers. Consider them for comparative context: